Professional
Added to YB: 2024-06-13
Pitch date: 2024-03-31
VKTX [bullish]
Viking Therapeutics, Inc.
-54.76%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.4B
Pitch Price
$81.97
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.51
P/E
-18.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Alger Small Cap Growth Fund Portfolio Holding: Viking Therapeutics, Inc.
VKTX: Biopharma co developing VK2809 for NASH/NAFLD & VK2735, a GLP-1 dual agonist for obesity. Q1 results showed statistically significant efficacy & safety for GLP-1 drugs. With 1/3 of US adults obese, GLP-1 drug has potential to address large market upon approval.
Read full article (1 min)